BriaCell Therapeutics Successfully Advances Towards Initiation of BriaVax(TM) Phase I/IIa Clinical Trial

Positive Release Testing Data From First Lot of Vaccine Submitted to FDA; Contract Negotiations Underway With Initial Clinical Site

BERKELEY, CA, USA and VANCOUVER, Canada I October 8, 2015 I BriaCell Therapeutics Corp (OTCQB:BCTXF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT") is pleased to announce that the Company has successfully advanced to the final stages of preparation for the upcoming Phase I/IIa study of BriaVax™.

BriaCell has submitted to the US Food and Drug Administration (FDA) final positive results its first lot of BriaVax™ which is to be used in BriaCell's upcoming Phase I/IIa clinical trial. These data were specifically requested by the FDA prior to initiating the BriaVax™ trial. Importantly, the data demonstrate that the first lot of BriaVax™ meets all purity, identity, potency and safety requirements for use in patients. The FDA is allowed thirty days to review and respond to the Company's submission.

"We are excited to have made this crucial advance towards initiating the clinical trial of BriaVax™," said Joseph Wagner, Ph.D., President and CEO of BriaCell. "Our first lot of BriaVax™ intended for patient use in the upcoming study has passed all testing required by FDA and we anticipate receiving approval to initiate the clinical trial by October 31. This first lot of BriaVax™ contains sufficient amounts to initiate the trial and treat multiple patients; additional lots are currently being manufactured so that we will have adequate material to both complete the clinical trial and support research and development work of BriaDx™, our companion diagnostic test. "

Dr. Wagner continued, "With the FDA submission complete, the Company has now focused on clinical operations, including the selection of our lead clinical trial site and the negotiation of a Clinical Trial Agreement, which is currently underway. Upon FDA approval, our lead Principal Investigator will submit the clinical trial protocol to the sites Institutional Review Board (IRB) for approval. With IRB approval the trial would be officially active and could begin enrolling patients.""

With the above in place, management feels that BriaCell remains well positioned to meet its guidance target date of enrolling first clinical patients during Q4 of this year. A potential added benefit of protocol activation could be additional non-dilutive grant eligibility, which the Company will pursue aggressively.


In addition, the Company also announces that, effective October 6, BriaCell's new US OTC-QB ticker symbol has been changed to BCTXF, in order to more closely align the US symbol with the ticker symbol used on the TSX Venture exchange.


BriaCell is a cancer immunotherapy biotechnology company developing a more targeted, less toxic approach to management of cancer. Immunotherapies have come to the forefront of the fight against cancer, because they harness the body's own immune system in recognizing and selectively destroying the cancer cells, sparing normal ones. Immunotherapies in addition to generally being more targeted and less toxic, have been shown to be more likely to prevent recurrence and are not expected to produce the serious side effects seen with chemotherapy.

The Company has demonstrated unique and unprecedented results, and is intent on building upon these results to further advance BriaVax™ through the FDA Clinical Trials in order to help cancer patients with no other options. The results of two FDA Phase I clinical trials have been encouraging in terms of both safety and efficacy in patients with advanced, stage-IV breast cancer. Most uniquely, BriaCell has achieved these results in patients who had prior failed the available therapies including various kinds of chemotherapy. In some cases, the lifespan was three to five times longer than expected. The results were targeted, with little to no side effects, and were achieved rapidly, with regression occurring within 6 weeks.

The Company is planning to advance its cancer immunotherapy technology in an FDA Phase I/II clinical trial with up to 24 breast cancer patients with advanced stages of solid tumors. The FDA-approved protocol has provision to allow testing the vaccine in selected patients with other cancers as well, including prostate, ovarian, pancreas, lung and bladder cancers among others. Although the focus of the Company is currently breast cancer, it recognizes that upon further proof of concept, its technology may be applicable to such other cancers as well. For further information, please refer to Company's website at or its youtube channel

SOURCE: BriaCell Therapeutics

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up